Isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin lymphoma (HL)

被引：0

作者：

Younes, A. ^{[5
]}

Kuruvilla, J. ^{[4
]}

Pro, B. ^{[5
]}

Wedgwood, A. ^{[5
]}

Li, Z. ^{[3
]}

Drouin, M. ^{[3
]}

Patterson, T. ^{[3
]}

Ward, R. ^{[2
]}

Martell, R. E. ^{[3
]}

Bociek, R. G. ^{[1
]}

机构：

[1] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE USA

[2] Pharm Corp, Clin Operat, Boulder, CO USA

[3] Drug Dev MethylGene Inc, Montreal, PQ, Canada

[4] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M4X 1K9, Canada

[5] Univ Texas Houston, MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

来源：

ANNALS OF ONCOLOGY | 2008年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：128 / 128

页数：1

共 50 条

[41] The Oral Selective Inhibitor of Nuclear Export ( SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin's Lymphoma (NHL) [J].

Kuruvilla, John ;

Byrd, John C. ;

Flynn, Joseph M. ;

Garzon, Ramiro ;

Porcu, Pierluigi ;

Wagner-Johnston, Nina ;

Savoie, Mary Lynn ;

Stone, Richard M. ;

Jacobsen, Eric D. ;

Mau-Sorensen, Morten ;

Brown, Peter de Nully ;

Baz, Rachid ;

Shal, Bijal ;

Flinn, Ian ;

Gabrail, Nashat ;

Kukreti, Vishal ;

Tiedemann, Rodger E. ;

Landesman, Yosef ;

Klebanov, Boris ;

Shacham, Eran ;

Saint-Martin, Jean-Richard ;

Marshall, Tracey ;

McCartney, John ;

McCauley, Dilara ;

Carlson, Robert ;

Norori, Sasha ;

Savona, Michael R. ;

Rashal, Tami ;

Mirza, Mansoor R. ;

Kauffman, Michael ;

Shacham, Sharon .

BLOOD, 2014, 124 (21)

[42] Phase II Study of Chidamide, a New Subtype-Selective Oral Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma [J].

Shi, Yuankai ;

Dong, Mei ;

Zhu, Jun ;

Zhou, Daobin ;

Huang, Huiqiang ;

Tu, Ping ;

Zhang, Weijing ;

Hong, Xiaonan ;

Zhao, Xielan ;

Sun, Jianfang ;

Liu, Yuehua ;

Qiu, Lugui ;

Shen, ZhiXiang ;

Feng, Jifeng ;

Ke, Xiaoyan .

BLOOD, 2015, 126 (23)

[43] A PHASE IB STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB COMBINED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA [J].

Palomba, M. L. ;

Till, B. G. ;

Park, S. I. ;

Morschhauser, F. ;

Cartron, G. ;

Marks, R. ;

Penuel, E. ;

Chitra, S. ;

Byon, J. C. H. ;

Popplewell, L. .

HAEMATOLOGICA, 2016, 101 :102-102

[44] Safety and Clinical Activity of Atezolizumab (Anti-PDL1) in Combination with Obinutuzumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma [J].

Till, Brian G. ;

Park, Steven I. ;

Popplewell, Leslie L. ;

Goy, Andre ;

Penuel, Elicia ;

Venstrom, Jeffrey M. ;

Liu, Bo ;

Fingerle-Rowson, Guenter ;

Byon, John ;

Woodard, Paul ;

Palomba, M. Lia .

BLOOD, 2015, 126 (23)

[45] Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed/refractory classical Hodgkin lymphoma: a meta-analysis of prospective clinical study [J].

A. Amraee ;

M. R. Evazi ;

M. Shakeri ;

N. Roozbeh ;

M. Ghazanfarpour ;

M. Ghorbani ;

J. Ansari ;

L. Darvish .

Clinical and Translational Oncology, 2019, 21 :1093-1103

[46] Efficacy of nivolumab as checkpoint inhibitor drug on survival rate of patients with relapsed/refractory classical Hodgkin lymphoma: a meta-analysis of prospective clinical study [J].

Amraee, A. ;

Evazi, M. R. ;

Shakeri, M. ;

Roozbeh, N. ;

Ghazanfarpour, M. ;

Ghorbani, M. ;

Ansari, J. ;

Darvish, L. .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (08) :1093-1103

[47] First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma [J].

Amengual, Jennifer E. ;

Lue, Jennifer K. ;

Ma, Helen ;

Lichtenstein, Renee ;

Shah, Bijal ;

Cremers, Serge ;

Jones, Simon ;

Sawas, Ahmed .

ONCOLOGIST, 2021, 26 (03) :184-e366

[48] Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial [J].

Shi, Yuankai ;

Su, Hang ;

Song, Yongping ;

Jiang, Wenqi ;

Sun, Xiuhua ;

Qian, Wenbin ;

Zhang, Wei ;

Gao, Yuhuan ;

Jin, Zhengming ;

Zhou, Jianfeng ;

Jin, Chuan ;

Zou, Liqun ;

Qiu, Lugui ;

Li, Wei ;

Yang, Jianmin ;

Hou, Ming ;

Zeng, Shan ;

Zhang, Qingyuan ;

Hu, Jianda ;

Zhou, Hui ;

Xiong, Yan ;

Liu, Peng .

LANCET HAEMATOLOGY, 2019, 6 (01) :E12-E19

[49] Chidamide, Oral Subtype-Selective Histone Deacetylase Inhibitor (HDACI) Monotherapy Was Effective on the Patients with Relapsed or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma [J].

Yan, Gao ;

Huang, Huiqiang ;

Li, Pengfei ;

Bing, Bai ;

Wang Xiaoxiao ;

Rong Qixiang ;

Li Zhiming ;

Cai Qingqing ;

Jiang, Wenqi .

BLOOD, 2017, 130

[50] Novel AKT Inhibitor Afuresertib In Combination With Bortezomib and Dexamethasone Demonstrates Favorable Safety Profile and Significant Clinical Activity In Patients With Relapsed/Refractory Multiple Myeloma [J].

Voorhees, Peter M. ;

Spencer, Andrew ;

Sutherland, Heather J. ;

O'Dwyer, Michael E. ;

Huang, Shang-Yi ;

Stewart, Keith ;

Chari, Ajai ;

Rosenzwieg, Michael ;

Nooka, Ajay K. ;

Rosenbaum, Cara A. ;

Hofmeister, Craig C. ;

Smith, Deborah A. ;

Antal, Joyce M. ;

Santiago-Walker, Ademi ;

Gauvin, Jennifer ;

Opalinska, Joanna B. ;

Trudel, Suzanne .

BLOOD, 2013, 122 (21)

← 1 2 3 4 5 →